Literature DB >> 19802520

Hepatic steatosis, carotid atherosclerosis and metabolic syndrome: the STEATO Study.

Claudio Carallo1, Gerardo Mancuso, Gaetano Mauro, Ferdinando Laghi, Bruno Madafferi, Concetta Irace, Agostino Gnasso, Faustina Scavelli, Ferruccio Dell'Aquila, Mosè Bartone, Francesco Gullo, Maria Ferraro, Vitaliano Spagnuolo, Maria Belmonte, Antonio Ferrara, Antonio Silvano Rotondaro, Nicola Brandolino, Francesca Parasporo, Francesco Scopelliti.   

Abstract

PURPOSE: Hepatic steatosis is frequently observed in subjects with metabolic syndrome (MS). In type 2 diabetics, it is independently associated with cardiovascular diseases. In order to confirm and extend this finding, a large group of patients with risk factors for atherosclerosis was studied.
METHODS: Carotid atherosclerosis was investigated by echo-Doppler, and hepatic steatosis by ultrasound and transaminase values. Strict exclusion criteria were chosen in order to avoid secondary forms of fatty liver and interference on transaminase values.
RESULTS: Among 970 enrolled patients, about 20% were diabetics, half had MS and 76% presented echographic hepatic steatosis. In multivariate analyses, fatty liver and MS were associated with carotid atherosclerosis [odds ratio (95% confidence intervals) 2.15 (1.27-3.63) and 1.72(1.12-2.64), respectively], whereas HOMA index was not. Aspartate aminotransferase and alanine aminotransferase were not independently associated with carotid atherosclerosis, whereas gamma-glutamyl transferase showed a link with atherosclerosis beyond MS and steatosis presence. The analyses of the 780 non diabetics recruited showed similar results.
CONCLUSIONS: The results of the present study demonstrate that hepatic steatosis measured by echography is associated with carotid atherosclerosis in a large population mostly carrying cardiovascular or metabolic risk factors, independently of MS, cardiovascular diseases, diabetes mellitus and/or insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19802520     DOI: 10.1007/s00535-009-0125-8

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  32 in total

1.  Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease.

Authors:  G Targher; L Bertolini; R Padovani; F Poli; L Scala; R Tessari; L Zenari; G Falezza
Journal:  Diabet Med       Date:  2006-04       Impact factor: 4.359

Review 2.  Gamma-glutamyltransferase, atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque.

Authors:  Michele Emdin; Alfonso Pompella; Aldo Paolicchi
Journal:  Circulation       Date:  2005-10-04       Impact factor: 29.690

3.  Gamma-glutamyl transferase: another biomarker for metabolic syndrome and cardiovascular risk.

Authors:  Scott M Grundy
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-01       Impact factor: 8.311

4.  Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients.

Authors:  Giovanni Targher; Lorenzo Bertolini; Felice Poli; Stefano Rodella; Luca Scala; Roberto Tessari; Luciano Zenari; Giancarlo Falezza
Journal:  Diabetes       Date:  2005-12       Impact factor: 9.461

5.  Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study.

Authors:  Roger K Schindhelm; Jacqueline M Dekker; Giel Nijpels; Lex M Bouter; Coen D A Stehouwer; Robert J Heine; Michaela Diamant
Journal:  Atherosclerosis       Date:  2006-05-08       Impact factor: 5.162

6.  Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease.

Authors:  Shinji Tamura; Iichiro Shimomura
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

7.  Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study.

Authors:  Monica Nannipieri; Clicerio Gonzales; Simona Baldi; Rosalinda Posadas; Ken Williams; Steven M Haffner; Michael P Stern; Ele Ferrannini
Journal:  Diabetes Care       Date:  2005-07       Impact factor: 19.112

8.  Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study.

Authors:  Douglas S Lee; Jane C Evans; Sander J Robins; Peter W Wilson; Irene Albano; Caroline S Fox; Thomas J Wang; Emelia J Benjamin; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-11-09       Impact factor: 8.311

9.  Nonalcoholic fatty liver disease and carotid atherosclerosis in children.

Authors:  Lucia Pacifico; Vito Cantisani; Paolo Ricci; John F Osborn; Elisa Schiavo; Caterina Anania; Eva Ferrara; Giuliano Dvisic; Claudio Chiesa
Journal:  Pediatr Res       Date:  2008-04       Impact factor: 3.756

10.  Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled type 2 diabetic patients.

Authors:  G Targher; L Bertolini; R Padovani; F Poli; L Scala; L Zenari; G Zoppini; G Falezza
Journal:  J Endocrinol Invest       Date:  2006-01       Impact factor: 4.256

View more
  2 in total

1.  The intertwisted correlations among non-alcoholic fatty liver disease, atherosclerosis, and metabolic syndrome.

Authors:  Haruhisa Nakao; Masashi Yoneda
Journal:  J Gastroenterol       Date:  2009       Impact factor: 7.527

2.  Acetylcholinesterase (AChE) inhibition aggravates fasting-induced triglyceride accumulation in the mouse liver.

Authors:  Shin-Ichi Yokota; Kaai Nakamura; Midori Ando; Hiroyasu Kamei; Fumihiko Hakuno; Shin-Ichiro Takahashi; Shigenobu Shibata
Journal:  FEBS Open Bio       Date:  2014-10-22       Impact factor: 2.693

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.